New combo aims to stop leukemia from coming back

NCT ID NCT07304011

Recruiting now Disease control Sponsor: University of California, Davis Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether giving olutasidenib with azacitidine, followed by olutasidenib alone as maintenance, can keep acute myeloid leukemia (AML) with an IDH1 mutation from returning. The study enrolls 28 adults who have already achieved remission after initial treatment. The goal is to see how many patients remain cancer-free at one year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Olutasidenib and azacitidine
What this could lead to: If successful, this could offer a new maintenance option to help prevent relapse in people with IDH1-mutated AML who have already responded to initial treatment.
What could go wrong: This is a small, early-phase trial (28 people) with no control group, so results may not apply broadly. Side effects from the drugs are possible, and the treatment may not prevent relapse.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

University of California Davis Comprehensive Cancer Center
RECRUITING

Sacramento, California, 95817, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.